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Abstract 
Hepatitis C and Hepatitis B, are common blood borne viruses that can cause acute hepatitis but are 
more clinically relevant because of the chronic infection that is associated with fibrosis the 
development of cirrhosis and Hepatocellular carcinoma. Both these viruses are becoming more 
common in the older population, due to the aging of generations exposed to the risk factors 
associated with infection; intra venous drug use, multiple sexual partners and men who have sex 
with men. This review will cover the natural history and epidemiology of these infections as well as 
the revolution in drug therapy that now allows cure of HCV infection and complete control of HBV 
infection. 
Introduction 
According to the World Health Organisation (WHO) Global Hepatitis report in 2017, approximately 
257 million individuals have chronic hepatitis B Virus (HBV) infection. Additionally, there are 71 million 
persons with chronic hepatitis C virus (HCV) seropositivity 1. In those who remain untreated; HBV and 
HCV may sequentially lead to chronic hepatitis, cirrhosis and hepatocellular carcinoma (HCC); which 
carry enormous morbidity and mortality. These complications account for 96% of deaths relating to 
viral hepatitis 1. 
As the aging population continues to grow the baby boomers of 1940-60 are now approaching their 
70th birthday. An updated overview of the UK population as of July 2017 from the office of national 
statistics showed the population to be becoming progressively older with 18% aged 65; and over 2.8% 
aged 85 and over.2 With this in mind the number of patients with viral hepatitis presenting to the 
medicine for the elderly services is ever increasing. There have been enormous advances in the 
understanding and management of the chronic infectious hepatitides (Hepatitis B (HBV) and Hepatitis 
C (HCV)) in recent years. Within this review we will focus on hepatitis B and C; specifically focussing 
on presentation, treatments and some of the associated morbidity within an aging populace. 
This is a pre-copyedited, author-produced version of an article accepted for publication in Age and Ageing following peer 
review. The version of record Kemp, L., et al. "New horizons in hepatitis B and C in the older adult", Age and Ageing (2018) 
is available online at: https://doi.org/10.1093/ageing/afy170.
Hepatitis B 
The first report of the virus was by Nobel Prize winner Baruch Blumberg in 1963; with the discovery 
of a new antigen termed Australian antigen (AuAg, now known as surface antigen) being reported 
publically.3 In the years to come AuAg became the first marker for viral hepatitis and following this 
Hepatitis B became a driving force for modern development of virus diagnostics and vaccines. 
Epidemiological studies estimate that one third of the world’s population has evidence of past or 
present infection.4 
Hepatitis B belongs to the hepadnavirus family. It is a composed of partially double-stranded viral DNA 
capable of reverse transcriptase.5 The complex viron is composed of a double stranded- DNA, 
nucleocapsid (HBcAg) and the outer surface of the viron, the hepatitis B surface antigen (HBsAg). 
Another nucleocapsid antigen is hepatitis B-e antigen (HBeAg).6 It is transmitted when blood, semen 
or another contaminated bodily fluid from a person infected with the virus comes into contact with 
mucus membranes or an open wound of someone who is virus naive. Transmission may be though 
sharing of needles, syringes or other drug injecting paraphrenalia, via sexual contact7 or by vertical 
transmission (from mother to child) at birth.8 
The natural history of the disease can vary from acute infection, inactive carrier state to progressive 
chronic hepatitis B even leading to cirrhosis and potentially hepatocellular carcinoma.  
The WHO recognises Hepatitis B as a major global health problem. The prevalence varies and is an 
estimated 1.6% in the WHO European Region and 0.7% in the WHO Region of the Americas.41 The UK 
falls into the lowest category of Hepatitis B prevalence, as determined by the WHO (0.1-0.5% of the 
population).9 Although acute HBV infection rates have fallen rapidly, the data from the Health 
Protection Agency indicated the frequency of chronic infection is increasing. Therefore it is likely that 
with increasing emigration patterns, particularly from those countries where Hepatitis B is more 
prevalent, with these persons also often bring additional affected family members. Not surprisingly, 
there is an increased prevalence in previously low predominance countries. In North America and 
Europe (including the UK) the main risk factors are birth in an endemic country, intravenous drug use 
and men who have sex with men. All of these risk populations are increasing in age, the teenagers of 
the “swinging 60’s” and the citizens from the decades of mass migration are now pensioners. Though 
these patients are poorly representative of the elderly population as a whole. 6 There are scattered 
reports of HBV outbreaks in nursing home residents in the literature; however, these are relatively 
historical; occurring in the 1970s. 10 
Clinical Manifestations 
Acute hepatitis B in older adults is usually mild and self-limiting. Infected elderly individuals often 
develop a subclinical or oligo-symptomatic hepatitis with a low rate of HBV clearance.11 In many cases 
the pattern of liver function derangement can be cholestatic in nature; which can lead to the 
performance of unnecessary tests and be miss leading in diagnosis of the condition as extrahepatic 
diagnosis such as pancreatic tumours or gall stones are considered first. Therefore, in every older 
patient presenting with elevated liver enzymes, it is suggested serological tests for hepatitis should be 
determined before proceeding to further investigation.12 The natural course of chronic HBV is 
influenced by a multitude of variables including age.13 The risk of progression to chronic hepatitis B is 
inversely related to age at the time of infection.  In infants progression to chronic hepatitis B has been 
reported in >90% of those infected, 25-50% of children aged 1-5 years old and progression from acute 
to chronic hepatitis B occurs in less than 5% of young adults, but is observed more frequently in the 
elderly.13 In Japan an outbreak in a nursing home lead to almost 60% of the infected becoming HbsAg 
carriers.12 There are  however some conflicting reports with regard to seroclearance with more than 
one study suggesting thatage >60 years has been shown to be an independent predictor for HbsAg 
clearance, but this has principally been demonstrated in Asian populations 14,15. 
The virus stages of chronic HBV infection are classified in EASL4 documents, this is illustrated in table 
1. The 5 phases are presented as a linear progression but it is important to note that patients can
move back and forth between the phases.
• Phase 1-The Immune tolerant phase is characterised by HBeAg positivity, high levels of HBV
replication, normal or low levels of aminotransferases, no liver necrosis and no or slow
progression to fibrosis, but is highly contagious and is the situation most commonly seen in
children and young adults.
• Phase 2-The Immune reactive phase again has HBeAg positivity, but lower replication rates,
increased or fluctuant levels of aminotransferase, on liver biopsy moderate to severe necro-
inflammation and more rapid progression to fibrosis. It is the most dangerous phase of
chronic HCV infection, with patients progressing to cirrhosis and liver failure. This is the
disease state targeted by current treatments, with the aim of suppressing viral replication.
• Phase 3- Inactive HB carrier state is defined by seroconversion of HBeAg to anti-HBe
antibody and low or undetectable levels of HBV DNA. Usually aminotransferases are normal.
There is a low risk of cirrhosis and HCC and this usually depends on the degree of damage
before this phase is reached. This phase can reactivate to immune reactive, especially with
inter-current illness, immunosuppressive therapy and some of the new biological agents.
• Phase 4- HBeAg negative CHB occurs in the presence of a HBV mutant virus that is not
supressed or only partially suppressed by the seroconversion from HBeAg to anti HBe-
antibodies. This may be apparent immediately on leaving the immune-reactive phase or may
become apparent after many years or decades of the inactive carrier state. It is
characterised by fluctuating HBV DNA and aminotransferase with an active hepatitis. There
is active liver disease with risk of progression to advanced fibrosis, cirrhosis and the
complications related to this, progression is usually slower than in the immune-reactive
phase
• Phase 5-HBsAg-negative phase is characterised by serum negative HBsAg and positive
antibodies to HBcAg (anti-HBc), with or without detectable antibodies to HBsAg (anti-HBs).
This phase is also known as ‘‘occult HBV infection”. Key to understanding this phase is the
recognition that these patient shad early phase of chronic infection and are different to the
resolved/cured acute infection, despite the fact they have the same immunological profile.
Most of these patients were previously regarded as cured and that is still indeed the case for
the majority, especially if they have minimal liver damage by the time they reach this stage.
The true occults still have cccDNA in their livers, which can lead to reactivation of infection
usually with inter-current illness, immunosuppressive therapy and some of the new
biological agents. Currently there are no reliable assays that can exclude the presence of
cccDNA in the liver
Table 1. Stages of chronic HBV infection 
Phase 
of 
chronic 
HBV 
Previous 
Name 
HBeAg Anti- HBe 
antibody 
HBV 
replication 
Aminotransferas
e level 
Necrosis 
fibrosis 
1 Immune 
tolerant 
Positive Negative High Normal or low None 
slow 
progression 
2 Immune 
reactive 
Positive Negative Lower Increased or 
fluctuant 
Mod/severe 
necrosis 
Rapid 
progression 
3 Inactive 
HB carrier 
Negative Positive Low Normal Low risk 
Low Risk 
4 HBeAg 
negative 
CHB 
Negative Positive Periodic re-
activation 
Fluctuant Active liver 
disease 
Risk of 
progression 
5 Occult 
HBV 
Negative Negative may persist 
in liver 
Normal dependent on 
duration of 
previous phases 
Vaccinations 
Childhood vaccinations are recommended routinely in many countries including the UK as of August 
2017 and also for those with increased risk of infection primary vaccination of adults.16 Studies into 
the response of elderly patients to the hepatitis B vaccination have found that when compared to a 
younger cohort, antibody response to primary vaccination was delayed.17 Within this specific study; 
no antibodies were detected after the first vaccination, and only 30% of the elderly participants 
showed an increase in their antibody levels after subsequent inoculation. By contrast, all but one of 
the younger participants in this, albeit small study, had mounted protective antibody levels 4 weeks 
after their second dose. This age- associated delay in primary immune response has also been 
described in yellow fever vaccination.18 Thought to be implicated in this decline in immune function 
in the elderly is T-cell dysfunction. Supporting this, in vitro studies have demonstrated normal 
production of antibodies to HBsAg when T cells from young individuals is added to the serum of elderly 
adults.19 Therefore, it is always worth ensuring appropriate antibody titres are achieved; with judicious 
use of booster courses as needed in this cohort of patients, the corollary of this is that patients with 
existing HBV vaccination my need boost vaccination. 
Treatments 
Treatments of chronic HBV have improved significantly. Nucleoside analogues (NAs), now form the 
backbone of the armamentarium against chronic HBV, with Interferon alpha still making a 
contribution. The aim of treatment is to supress the level of viral replication as this is strongly 
associated with cirrhosis and HCC. This can be achieve immunologically or pharmacologically. 
Interferon therapy stimulates an immunological response that can lead to virological cure in up to 30% 
of cases, but with a formidable side-effect profile, success rates are lower in older patients. 
Pharmacological therapy is NAs that suppress viral replication by direct interference in the replication 
mechanism, these are highly effective, achieving complete suppression in most patients. However 
they have to be taken long term, as the suppression last only as long as the half-life of the drug. Overall, 
NAs have a reasonable side effect profile and require infrequent monitoring. They are better tolerated 
and are the preferred treatment for those with significant fibrosis, cirrhosis or undergoing transplant. 
The need for treatment is determined by overall evidence of viral activity, seroconversion of Hepatitis 
e-Ag, evidence of necroinflammation and presence or absence of established liver disease, and should 
be co-ordinated by a specialist in infectious hepatitis.20
With regards to specific treatment strategies for elderly patients with chronic HBV; those with 
deteriorating renal function or osteoporosis, treatment with Tenofovir Alafenamide and Entacavir has 
been shown to have less systemic effects and is preferred. It is therefore suggested that patients at 
risk of deteriorating renal function especially those over 60 if already on Tenofovir Disoproxil are 
considered for a switch. 4  
Hepatitis C (HCV) 
The hepatitis C virus (HCV) is a blood borne, hepatotropic RNA virus which can cause both acute and 
chronic infection. Acute HCV infection is rarely symptomatic; with one large meta-analysis study 
suggesting spontaneous clearance rates of the virus of 26%.21 Those who have been unable to 
spontaneously clear the virus go on to develop chronic hepatitis C which, similar to the acute phase, 
is usually asymptomatic 22 Chronic hepatitis C is defined as the persistence of HCV RNA in an 
individual’s blood for at least 6 months after the onset of acute infection. This can therefore cause 
significant intrahepatic damage before it is clinically recognized. Chronic HCV infection predisposes 
the individual to liver fibrosis, cirrhosis and hepatocellular carcinoma (HCC), conditions associated 
with significant morbidity and mortality22. As well as this, 1-2% of chronically infected individuals will 
develop extrahepatic manifestations of the disease commonly cryoglobulinemia, 
membranoproliferative glomerulonephritis and vitiligo. Data also suggests an association between 
chronic HCV infection and the development of both Hodgkins and non-Hodgkins lymphoma23. HCV 
infection is diagnosis on the combination of a positive HCV antibody in a patient serum, which 
indicates current or previous infection (the antibody is not protective against further infection) and 
the detection of HCV RNA in a patients serum which indicates active infection requiring treatment. 
The combination of positive antibody and negative HCV RNA indicates spontaneous or treatment 
induced cure. 
The rate of chronic HCV infection has been shown to be reliant on many factors including gender, 
ethnicity, age at the time of infection and the presence of jaundice during the acute infection23. Of 
those with chronic HCV infection; it is estimated that between 5 and 20% of individuals will go on to 
develop liver cirrhosis. In these cirrhotic patients, there is a 25% risk of progressing to end-stage liver 
disease and 3-5% annual risk of developing HCC25,26. It is therefore unsurprising; that the Centres for 
Disease Control and Prevention (CDC) have reported that worldwide, chronic HCV infection is the 
leading cause for requiring a liver transplant27. 
The virus is transmitted by percutaneous exposure to infected blood. The leading mode of 
transmission since the 1970’s has been injection drug use however other modalities of transmission 
include the reuse or inadequate sterilisation of medical equipment, haemodialysis (typically 
unscreened blood products before 1992), healthcare work and military service13. Although 
uncommon; HCV can be transmitted through sexual activity, tattoos and vertically from mother to 
baby. Injection drug use remains the leading mode of transmission in the developed world whilst 
unsafe healthcare practice accounts for the majority of new infections in the East Mediterranean 
countries1. With regards to HCV testing, the WHO recommend screening for individuals at an 
increased risk of infection.  
Hepatitis C appears to be endemic in most areas of the world. With an estimated global prevalence of 
over 71 million people (1% of the global population) and an annual incidence of between 3 and 4 
million cases1, chronic HCV infection is one of the leading causes of chronic liver disease worldwide. 
There are considerable variations in the age and geographic prevalence of HCV infection and 
genotype; rates of disease differ across and within each country. According to statistics published by 
the WHO in 2017, the highest prevalence of HCV infection was found in the Eastern Mediterranean 
region (2.3%) followed by the European region (1.5%)1. Data has shown that countries in the eastern 
and southern parts of Europe have a higher HCV prevalence than countries in the northern or western 
regions. The reported prevalence of HCV infection in the general population ranges from 0.1% in the 
Netherlands, Ireland and Belgium to 5.9% in Italy. Other counties with reasonably high rates of HCV 
include Romania (3.2%), Latvia (2.4%) and Greece (2.2%)29. 
With regards to the incidence of HCV in the USA, there has been a disproportionate birth-related 
cohort of infection. It has been recognised that up to 80% of individuals infected with HCV were born 
during the ‘baby boom’ between 1946 and 196430. This generation constitute the largest birth cohort 
in US history and reflects a marked increase in births following World War II. Data suggests that 
individuals born during this period are five times more likely to have chronic HCV infection than other 
adults31. The reasons for this are not entirely understood however it is believed that the baby boomers 
became infected with HCV between the 1960’s and 1980’s when transmission of this virus was highest. 
It is thought that in this generation, the introduction of new pathways of HCV transfer coupled with a 
lack of knowledge on the prevention of spreading blood-borne viruses has created a higher disease 
prevalence. To this day, the majority of people with chronic HCV infection are unaware of their 
condition. Even in those with a diagnosis, many do not know how or when they became infected31. 
The US Census Bureau have projected that in 2030, the elderly population will comprise approximately 
20% of the total US population32. Given the natural history of chronic HCV infection and its high 
prevalence amongst this cohort, it is no surprise that the incidence of HCC in the USA has tripled over 
the past decade33. The high seroprevalence amongst this age group coupled with the discovery of 
highly effective anti-viral therapy prompted the CDC to change HCV screening recommendations in 
the US. In 2012; the CDC recommended a universal ‘one-time testing’, without ascertaining previous 
HCV risk, for individuals born between 1945-196524. Despite this new recommendation, the 2015 
National Health Interview survey revealed that only 13.8% of this cohort had been tested for HCV. This 
slow uptake in screening is likely to be due to a lack of awareness amongst both patients and 
physicians to these new recommendations. Other influences may include the patient’s unapparent 
symptoms and barriers to preventative medicine34. 
Considering it is estimated that less than 15% of patients with chronic HCV infection are aware of their 
status, it is important to have a low threshold to investigate patients presenting with signs and 
symptoms of liver failure35. In comparison with younger individuals, adults aged over 65 are more 
likely to present with complications of liver cirrhosis namely hepatic failure and HCC as an initial 
manifestation of HCV infection36. Features of decompensated liver cirrhosis include upper 
gastrointestinal bleeding secondary to oesophageal varices or portal hypertensive gastropathy, 
development of abdominal ascites, hepato-renal syndrome and hepatic encephalopathy23. The overall 
morbidity and mortality rates associated with the complications of acute and chronic liver disease are 
much higher in the elderly population. This is partly due to a higher prevalence of co-morbid conditions 
but also because physiological changes related to aging make compensation and recovery difficult13. 
The treatment options available for advanced liver cirrhosis and HCC in elderly patients who do 
survive, are limited. In light of the new antiviral therapies, HCV infection is now recognised as curable. 
Emphasis should be placed on screening the at risk ‘baby boomer’ population as initiation of HCV 
eradication treatment may halt progression to advanced cirrhosis and its associated complications.  
Treatments 
Pharmacological treatment of HCV infection has been revolutionised over the past decade. The new 
direct acting antiviral regimens offer a sustained virological response (SVR) of 90-95% in patients with 
HCV-related liver cirrhosis including those with decompensated disease26. The efficacy and safety of 
treating HCV infection in elderly patients has previously been debated due to issues with compliance, 
co-morbid conditions and the side effect profiles of the medications. However, the introduction of the 
newer, safer agents with lesser contraindications, provide highly effective therapeutic options for 
these patients who have previously been deemed unsuitable for treatment. Observational studies 
have revealed that in patients aged over 65, the first generation protease inhibitor-based regimens 
has a similar efficacy to that of younger patients, albeit with more frequent adverse effects37. 
Therefore the decision of whether to commence an elderly patient on HCV treatment should be 
guided by an assessment of liver-disease dependant and comorbidities dependant life expectancy and 
drug-drug interactions rather than their biological age. There is no licensed vaccine for HCV presently. 
 
Cirrhosis and Hepatocellular Carcinoma 
The liver is formed by parenchymal cells (hepatocytes) and other non-parenchymal cells; 
liver sinusoidal endothelial cells (LSECs), Kupffer cells (KC) and hepatic stellate cells (HSC). 
These cells line the walls of hepatic sinusoids. Both parenchymal and non parenchymal cells 
are involved in the initiation and progression of liver fibrosis and cirrhosis.42 While the cause 
of liver disease is often multifactorial liver cirrhosis, in both chronic HBV and HCV infection, 
alcohol consumption can accelerate disease progression as can the metabolic syndrome, 
there is the final pathological result and there are common pathological characteristics in all 
cases of cirrhosis. The cycles of viral assault on the liver and immunological response results 
in degeneration and necrosis of hepatocytes, replacement of liver parenchyma by fibrotic 
tissue and regenerative nodules and loss of liver function and ultimately cirrhosis42, the 
cumulative effect of this at the time of viral cure or suppression determines the long 
prognosis and risk of development of the complications of cirrhosis and HCC. 
 
Liver cirrhosis is the major risk factor for the development of Hepatocellular carcinoma.43 
Hepatocellular carcinoma is the fifth most common cancer worldwide and the second most common 
cause of cancer-related death.38 Although HCC is more common in cirrhotic patients it can also develop 
in non-cirrhotic patients, this is well recognised in HBV patients, and there are now case reports of 
HCC in non-cirrhotic HCV patients. HCC arises in a cirrhotic background in 90% of cases.44 It is therefore 
recommended by NICE that patients with cirrhosis should undergo 6 monthy screening which entails 
and ultrasound scan with or without alpha-fetoprotein checking. For those with cirrhosis and HBV 
surveillance should include alpha-fetoprotein testing.  The aim of surveillance is to achieve a reduction 
in the overall mortality and should be cost effective.45 The risk of developing HCC is known to be age 
dependant and with the prospect of an aging population invariably implying that rates of HCC will 
invariably increase.  
 
Male-to-female preponderance is greater than 2:1 with liver cancer, and approximately 83% of the 
estimated 782,000 new HCC cases in 2012 occurred in less developed regions of the world. East and 
South Asia plus sub-Saharan Africa were the regions of highest incidence, Southern Europe and North 
America being of intermediate incidence, and Northern Europe and South Central Asia being the 
regions of lowest incidence.39 
Treatment for HCC has advanced significantly in the last few decades with there being many treatment 
options now available. Treatments can include surgical resection or liver transplantation, TransArterial 
catheter ChemoEmbolisation (TACE), percutaneous radiofrequency ablation, percutaneous ethanol 
injection, percutaneous microwave coagulation therapy and molecular targeted therapy. Current 
guidelines for the management of HCC do not stratify for age.40 Irrespective of these advances 
however, the overall mortality associated with Non-transplanted HCC is significant. 
Conclusion 
Although in this day and age, both HBV and HCV infection are generally associated with intravenous 
drug use, non-sterile healthcare practice and unsafe sexual practice, it is important to remember, 
particularly in the US, the data has shown that one of the highest risk groups for infection is those 
aged over 65. It is therefore imperative that healthcare workers test elderly patients presenting with 
signs or symptoms of chronic or decompensated liver disease.  
 
With the introduction of the new and effective antivirals, the long-term sequelae of HCV induced liver 
disease and subsequently high morbidity and mortality rates in the elderly could become a problem 
of the past. Whilst therapies for HBV lag behind somewhat; there are increasing efforts to identify 
affected individuals early, prior to the development of chronic liver disease and its associated sequelae 
in an attempt to improve outcomes. Emphasis should also be toward effective vaccination 
programmes for HBV given the presently incurable nature of the virus.  
 
It is imperative that we appreciate the burden of undiagnosed HBV and HCV that exists within our 
cohort of elderly patients; and ensure appropriate screening is undertaken at opportune times.   
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